Tumor angiogenesis, macrophages, and cytokines

Advances in Experimental Medicine and Biology

Volumn 476, Issue , 2000, Pages 267-284

  Bando, H ^a   Toi, M ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; CHEMOKINE; CYTOKINE; GELATINASE A; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 2; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; BINDING SITE; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; MACROPHAGE; PRIORITY JOURNAL; STROMA CELL;

EID: 0034471781     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4221-6_21     Document Type: Conference Paper

References (114)

1. Angiogenesis in cancer, vascular, rheumatoid and other disease
2. Angiogenic factors
3. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool
4. Clinical significance of the determination of angiogenic factors
5. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer
6. Expression of platelet-derived endothelial cell growth factor in human breast cancer
7. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma
8. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma
9. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients
10. Vascular endothelial growth factor and lymph node metastasis in primary lung cancer
11. Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas
12. Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma
13. Vascular endothelial growth factor expression in early stage ovarian carcinoma
14. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma
15. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer
16. Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck
17. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma
18. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
19. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma
20. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation an tumour angiogenesis
21. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth
22. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
23. Modulation of VEGF production by pH and glucose in retinal Muller cells
24. Production of vascular endothelial growth factor by murine macrophages: Regulation by hypoxia, lactate, and the inducible nitric oxide synthase pathway
25. Up-regulation of vascular endothelial growth factor in response to glucosedeprivation
26. Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: Survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells
27. Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-alpha: Balance between growth and death signals
28. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression
29. bcl-2 gene prevents apoptosis of basic fibroblast growth factor-deprived routine aortic endothelial cells
30. Thymidine phosphorylase is angiogenic and promotes tumor growth
31. Role of thymidine phosphorylase activity in the angiogenic eFFect of platelet-derived endothelial cell growth factor/thymidine phosphorylase
32. Angiogenic activity of enzymes
33. Thymidine phosphorylase is angiogenic and promotes tumor growth
34. Differential angiogenic pathways characterize superficial and invasive bladder cancer
35. Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor
36. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine
37. The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo
38. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder
39. Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase
40. Tumor angiogenesis and expression of thymidine phosphorylase/platelet derived endothelial cell growth factor in human gastric carcinoma
41. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma
42. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma
43. Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: Impact on tumour neoangiogenesis and survival
44. Expression of thymidine phosphorylase is associated with a poor prognosis in patients with ductal adenocarcinoma of the pancreas
45. Co-ordination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: Prognostic implications
46. Expression of the thymidine phosphorylase gene in epithelial ovarian cancer
47. Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF
48. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy
49. Low levels of basic fibroblast growth (bFGF) are associated with a poor prognosis in human breast carcinoma
50. A phase II study of 5-aza-2′deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer
51. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients
52. Basic fibroblast growth factor expression as a predictor of prognosis in pediatric high-grade gliomas
53. Tumor-associated macrophages in neoplastic progression: A paradigm for the in vivo function of chemokines
54. Properties of the novel proinflammatory supergene intercrine cytokine family
55. How the extracellular matrix and macrophages contribute to angiogenesis-dependent diseases
56. Secretion of epidermal growth factor by macrophages associated with breast carcinoma
57. Transforming growth factor-β1 stimulates macrophage urokinase expression and release of matrix-bound basic fibroblast growth factor
58. Cathepsin D Immunostaining in Paraffin-Embedded Breast Cancer Cells and Macrophages
59. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response
60. Urokinase and macrophages in tumor angiogenesis
61. Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer
62. Significance of membrane type I matrix metalloproteinase expression in breast cancer
63. Interleukin-4 is a potent mitogen for capillary endothelium
64. Novel biological function of Interleukin-4: Formation of tube-like structure by vascular endothelial cells in vitro and angiogenesis in vivo
65. IL-4 Regulates endothelial cell activation by IL-I, tumor nerosis factor, or IFN-γ I
66. Interleukin-4 stimulates Expression of Urokinase-Type-Plasminogen activator in cultured human foreskin microvascular endothelial cells
67. IL-4 acts synergistically with IL-Iβ to promote lymphocyte adhesion to microvascular endothelium by induction of vascular cell adhesion molecule-1
68. Interleukin 4 or oncostatin M induces a prolonged increase in P-selectin mRNA and protein in human endothelial cells
69. Generation and analysis of interleukin-4 deficient mice
70. Disruption of the murine IL-4 gene blocks Th2 cytokine responsers
71. Effect of in situ retroviral interleukin-4 transfer on established intracranial tumors
72. Inhibition of angiogenesis by interleukin 4
73. Interleukin-8 as a macrophage-derived mediator of angiogenesis
74. Interlerkin-8 stimulates angiogenesis in rats
75. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice
76. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis
77. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice
78. Interleukin 8: An autocrine growth factor for malignant mesothelioma
79. Expression of interleukin-8 correlates with vascularity in human gastric carcinomas
80. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice
81. Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis
82. Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma
83. Coexpression of interleukin-8 receptors in head and neck squamous cell carcinoma
84. Role of angiogenic factors: Coexpression of interleukin-8 and vascular endothelial growth factor in patients with head and neck squamous carcinoma
85. Two types of mouse helper T cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th 1 clones
86. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th 1 cells
87. Interleukin 10
88. Expression of IL-10 activity by Epstein-Barr virus protein BCRFI
89. Differencial effects of interleukin-4 and -10 on interleukin-2-induced interferon-γ synthesis and lymphokine-activated killer activity
90. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: Potential inhibition of angiogenesis
91. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration
92. Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis
93. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion
94. Role of interleukin 10 and transforming growth factor β1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthoropic implantsi in severe combined immunodeficiency mice
95. Regulation of local host-mediated anti-tumor mechanisms by cytokines (Direct and indirect effects on leukocyte recruiment and an angiogenesis
96. IL-12 regulates VEGF and MMPs in a murine breast cancer model
97. Interferon γ-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis
98. Interferon-γ-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases
99. Properties of the novel proinflammatory supergene "intercrine" cytokine family
100. Human interferon-inducible protein 10: Expression and purification of recombinant protein demonstrate inhibition of early human hematopoietic progenitors
101. Cytokine loops involving interferon-γ and IP-10, a cytokine chenotactic for CD4+ lymphocytes: An explanation for the epidermotropism of cutaneus T-cell lymphoma?
102. Purification of a monocyte chemotactic factor secreted by nonhuman primate vascular cells in culture
103. Identification of high affinity receptors for human monocyte chemoattractant protein-1 on human monocytes
104. MCP and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions
105. IL-4 potentiates IL-1 beta-and TNF-alpha-simulated IL-8 and MCP-1 protein production in human retinal pigment epithelial cells
106. Monocyte chemotactic factors released from type II pneumocyte-like cells in response to TNF-alpha and IL-1 alpha
107. Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line
108. Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells
109. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer
110. CD40 ligand-CD40 interaction induces chemokines in cervical carcinoma cells in synergism with IFN-gamma
111. Urinary levels of monocyte chemo-attractant protein-1 correlate with tumour stage and grade in patients with bladder cancer
112. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
113. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium